

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Hua Zhu Ke :

APPLICATION NO.: 10/596,504 : Examiner: To Be Assigned

FILING DATE: To Be Assigned : Group Art Unit: To Be Assigned

TITLE: TREATMENT OF CONDITIONS THAT  
PRESENT WITH LOW BONE MASS BY  
CONTINUOUS COMBINATION THERAPY  
WITH SELECTIVE PROSTAGLANDIN EP<sub>4</sub>  
RECEPTOR AGONISTS AND AN ESTROGEN

Mail Stop: Amendment  
Hon. Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

If a fee is believed to be due, authorization is hereby authorized to charge Deposit Account No. 16-1445 the appropriate fee.

Patent Application  
Attorney Docket No. PC23170A

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: 07 July 2006  
Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-6645

/ John A. Wichtowski /  
John A. Wichtowski  
Attorney for Applicant(s)  
Reg. No. 48,032